4–7 May 2023
4–7 May 2023
Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. In more than 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of mRNA, to an enterprise with a diverse investigational pipeline of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and rapid speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing.
altona Diagnostics GmbH
altona Diagnostics is a medical diagnostic company that develops and manufactures in vitro diagnostic tests for the PCR based detection of pathogens such as viruses, bacteria or parasites. Headquartered in Hamburg-Altona, Germany, altona Diagnostics is privately owned and employs more than 350 people worldwide. The company has been in the molecular diagnostics business for over 20 years and is ISO 13485 certified. altona Diagnostics sells its registered products to private and clinical laboratories globally through subsidiaries and more than 40 distribution partners.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
DiaSorin Poland sp. z o.o.
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".
More info at www.diasoringroup.com
The European Research Infrastructure on Highly Pathogenic Agents (ERINHA) is dedicated to the study of emerging and re-emerging pathogens of high incidence. It brings together the main European high containment facilities (BSL3/3+; BSL4) that support research into highly infectious diseases such as CCHF, Ebola, Marburg and Nipah virus. ERINHA provides access to the expertise and resources of its members' high containment facilities, enabling a broad community of researchers, including from Africa, to conduct research on these deadly pathogens. Currently, free access to these facilities is provided by the EU-funded Integrated Services for Infectious Disease Outbreak Research (ISIDORe) project.
ERINHA's mission is to advance research on high-impact (re)emerging diseases and to contribute to the protection of human health by improving European and global preparedness and response to highly pathogenic infectious threats.
For more information visit our website erinha.eu/ , follow us on social networks Twitter & LinkedIn.
ISIDORe:bringing together all European research services to study pathogens with epidemic potential.
The Integrated Services for Infectious Disease Outbreak Research (ISIDORe) project was launched with the ambition to provide a new approach to research on outbreak preparedness and response in Europe. Funded by the EU and coordinated by the ERINHA infrastructure, ISIDORe brings together resources from all major European research infrastructures and infectious disease networks. As such, the programme provides free access to an unprecedented integrated portfolio of cutting-edge research services, driven by the One Health approach and dedicated to the study of epidemic-prone diseases.
In its first year, the ISIDORe programme supported research projects on rapid response and preparedness for epidemics with calls for proposals targeting SARS-CoV-2 variants, monkeypox virus and a wide variety of pathogens on the priority list of pathogens set up under the recommendations of key agencies and initiatives such as WHO, WHO, UNAIDS, ECDC, HERA, EC, WEA, ECPI, GLOPID-R, EFPIA, and crucial for epidemic preparedness.
We provide free transnational access to a comprehensive portfolio of high-quality services - the most advanced, innovative, and cutting-edge available - to support the projects of scientists from the Academy or the private sector in Europe and internationally.
Pandemic preparedness calls covering Risk Group 4 pathogens, vector-borne pathogens, respiratory pathogens, and pathogen X are still open.
For more information visit our website https://isidore-project.eu/ , follow us on social networks Twitter & LinkedIn.
Contact us: firstname.lastname@example.org
EUROIMMUN is a leading international provider of medical laboratory products with an extensive portfolio for infection diagnostics. Its product range includes indirect immunofluorescence tests, ELISAs, immunoblots and chemiluminescence immunoassays for detection of antibodies against many different viruses, bacteria and parasites. Avidity formats, CSF assays and microarrays for multiplex detection of infectious agents are also available. EUROIMMUN offers a complete package for COVID-19 diagnostics, encompassing tests for direct detection of SARS-CoV-2 and comprehensive analysis of immune responses. State-of-the-art instruments and software provide efficient automation of analyses. EUROIMMUN’s infection diagnostics range complements its products for autoimmune, allergy and molecular genetic diagnostics.
GeneTex is a multinational antibody manufacturer with 25 years of experience producing immunological reagents for biomedical research. The company maintains a broad range of primary antibodies in polyclonal and hybridoma-based monoclonal formats, but now prioritizes its robust recombinant monoclonal antibody production platform. A core focus area of GeneTex’s catalog is molecular virology, and the company has established an extensive portfolio of highly validated and cited reagents against flavivirus pathogens, SARS-CoV-2, influenza viruses, Ebola virus, hepatitis viruses, HIV, enteroviruses, and human papillomavirus. New products against emerging infectious diseases, RSV, VEEV, Chikungunya virus, and porcine viruses are being continuously developed by GeneTex.
NaNoEXPO Sp. z o.o.
The NanoExpo Company develops reagents and materials as well as provides services for interdisciplinary biotechnology research. Our "Made for Virology" product line includes a variety of quick and easy molecular virology solutions. Experts at NanoExpo specialize in the design and production of native viral antigens in a variety of expression systems.
To meet customer demands, we are continuing to create cutting-edge antigens in the form of biological nanostructures (VLPs, chimeric VLPs and artificial bio nanostructures). Through our artificial intelligence-based Peptaim Platform, we support antiviral research, vaccine development, diagnostics, and basic science by studying peptide-protein interactions from virtually generated peptide libraries.
Discover Promega, a trusted partner in scientific discovery for 40+ years. Offering innovative molecular biology solutions for gene, protein, and cell analysis, our customized offerings are tailored to the unique needs of our customers. With a range of reagents, instruments, and services, we simplify your research and enhance results. Our compact sequencer, bioassays, and reporter assays take your drug discovery to the next level. Committed to customer satisfaction, our focus is on supporting research and development with technical advice and helpful service. Let's work together to power ideas for tomorrow.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Thermo Fisher Scientific
Thermo Fisher Scientific supports you to accelerate your vaccine design and development. Get timely structural insights using our end-to-end cryo-electron microscopy (cryo-EM) workflow solution that can image entire viruses, specific viral proteins, and host-pathogen molecular interactions in 3D in their near-native state! Additionally, our cryo-EM innovation can help improve the design and manufacturing of viral vector vehicles.
As the world’s leading animal health company, we are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. In 2020, we generated revenue of $6.7 billion with ~11,300 employees. For more, visit www.zoetis.com.
Adamed Pharma S.A.
Adamed Pharma is a Polish research- and patent-based pharmaceutical and biotechnology company with 100 percent Polish capital. Established in 1986, today it employs almost 2500 people and owns 2 production plants in Poland as well as one in Vietnam. The pillars of the company's development are foreign expansion and investments in increasing the production of medication in Poland and in innovation. For more than 20 years, the company has been conducting its own innovative R&D work, for which it has allocated PLN 2.1 billion since 2001. Adamed is currently implementing projects in three therapeutic areas: oncology, diabetology and neuropsychiatry. The company's intellectual property is protected by over 200 patents in most countries around the world, and its portfolio includes over 500 products. Each year, the company produces over 2.6 billion tablets offered in over 70markets around the world. It ensures general access to therapy for millions of patients in Poland and many other countries.
Adamed Pharma S.A
Rejestracja: Krajowy Rejestr Sądowy, prowadzony
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services.
Science is our passion; it drives us to collaborate, develop, and manufacture award-winning tools that help researchers achieve reproducible and consistent results. Whether you are at the cutting edge of academic research, translating basic discoveries to therapeutic leads, or at a facility that requires the highest level of diagnostic testing, our innovative products and services provide the solutions you need to achieve success.
CureVac Corporate Services GmbH
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S.